Revance is a biotechnology pioneer establishing a new category of long-lasting neuromodulators. By fusing cutting-edge science with the entrepreneurial spirit of Silicon Valley, we are daring to make a difference by introducing aesthetic and therapeutic treatments that meaningfully transform patient experiences.
Our lead investigational product, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.
In aesthetics, we have successfully completed a Phase 3 program for DAXI in glabellar (frown) lines, delivering unprecedented efficacy and duration of effect, and we are pursuing U.S. regulatory approval in 2020. The anticipated approval of DAXI would represent the first major innovation to hit the neuromodulator market in 30 years.
We are also evaluating DAXI in forehead lines and lateral canthal lines (crow’s feet), as well as three therapeutic indications – cervical dystonia, adult upper limb spasticity, and plantar fasciitis, with plans to study migraine. Beyond DAXI, Revance has begun development of a biosimilar to BOTOX®, which would compete in the existing neuromodulator marketplace.
We are dedicated to making a difference by transforming patient experiences. We believe in leaving bureaucracy behind. We value speed, audacity, grit and empathy, and empower our teams to reimagine the status quo.